FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
|Articles|October 1, 2004
- Pharmaceutical Technology-10-01-2004
- Volume 2004 Supplement
- Issue 7
The Integrity Tests: Choosing Diffusive Airflows of Bubble Points
Author(s)Maik W. Jornitz
This article critiques the diffusive-airflow and bubble-point tests for their comparative suitability for integrity testing in pharmaceutical processes.
Advertisement
Articles in this issue
about 22 years ago
Choosing the Proper Filterabout 22 years ago
Validation of Sterile Filtrationabout 22 years ago
Principles of Steam-In-Placeabout 22 years ago
Single-Use Technology for Sterilizing-Grade FiltrationAdvertisement
Related to this article
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
3
Nitrosamine Problems and Industry Solutions: PharmTech Explained
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5